Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
44.44
-0.41 (-0.91%)
Apr 25, 2025, 12:29 PM EDT - Market open
Protagonist Therapeutics Employees
Protagonist Therapeutics had 126 employees as of December 31, 2024. The number of employees increased by 14 or 12.50% compared to the previous year.
Employees
126
Change (1Y)
14
Growth (1Y)
12.50%
Revenue / Employee
$3,447,881
Profits / Employee
$2,184,032
Market Cap
2.73B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
PTGX News
- 2 days ago - Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Accesswire
- 8 days ago - Protagonist Therapeutics Reports Granting of Inducement Award - Accesswire
- 5 weeks ago - Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Accesswire
- 6 weeks ago - Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It - Seeking Alpha
- 6 weeks ago - Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga
- 7 weeks ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 2 months ago - Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Accesswire
- 3 months ago - Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck - Seeking Alpha